Sensorion SA (EPA:ALSEN)

France flag France · Delayed Price · Currency is EUR
0.350
-0.013 (-3.58%)
Mar 2, 2026, 11:32 AM CET
-42.62%
Market Cap 109.03M
Revenue (ttm) 5.65M
Net Income (ttm) -28.09M
Shares Out 300.35M
EPS (ttm) -0.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,023,535
Average Volume 2,183,568
Open 0.354
Previous Close 0.363
Day's Range 0.336 - 0.357
52-Week Range 0.154 - 0.612
Beta 0.55
RSI 61.01
Earnings Date Mar 16, 2026

About Sensorion

Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. The company’s product portfolio includes SENS-401 SSNHL, which has completed Phase 2b clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2a clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2a clinical which is an orally available small molecule protecting and preserving inner ear tissue from damage, responsible for hearing ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 68
Stock Exchange Euronext Paris
Ticker Symbol ALSEN
Full Company Profile

Financial Performance

In 2024, Sensorion's revenue was 6.65 million, an increase of 16.76% compared to the previous year's 5.70 million. Losses were -25.97 million, 17.7% more than in 2023.

Financial Statements

News

Sensorion: CEO Nawal Ouzren To Resign

(RTTNews) - Sensorion (ALSEN.PA) announced that Nawal Ouzren, CEO and a Director, is stepping down from both posts due to a personal matter incompatible with serving as Chief Executive Officer. Amit M...

13 days ago - Nasdaq

Sensorion reports 1H results

5 months ago - Seeking Alpha

Sensorion reports FY results

1 year ago - Seeking Alpha